Some items on our site have recently moved. Visit our News Hub for selected articles, special reports, podcasts and other resources.
AbbVie, Allergan well-positioned for unconditional clearance in Brazil
22 Oct 2019 12:41 pm by Ana Paula Candil
AbbVie’s $63 million merger with Allergan is well-positioned for unconditional antitrust clearance in Brazil, MLex has learned.
Approval by the Administrative Council for Economic Defense, or CADE, is expected to be announced soon.
AbbVie and Allergan submitted merger paperwork on Aug. 22, but amended their notification form, pushing the review deadline to Nov. 14.
AbbVie and Allergan are listed on the New York Stock Exchange.
Related Articles
-
Chip dealmakers from the US and elsewhere are likely to be bracing for new challenges in their global buying spree. -
Mergers and US antitrust filings are expected to remain strong through the first half of 2021, fueled by acquisitions in the wake of the global pandemic. -
A recommendation in the House Judiciary Committee’s 452-page report on competition in digital markets is sparking debate.